Keymed Biosciences Inc (hkse:02162) Share Price

Company Profile

Business description
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
Contact
No. 18 BioTown Middle Road
Building D2
Tianfu International BioTown, Chengdu
Sichuan610219
CHN
T: +86 2888610620
https://www.keymedbio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,258

Recommended

These companies are our top choices for investors wanting to boost Aussie exposure.

Simonelle Mody | 15 July 2025

We raise our risk and uncertainty rating to reflect the impact of the ruling.

Esther Holloway | 13 July 2025

Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.

Sarah Hansen | 10 July 2025

Index	Last price	Change	% Change
All Ordinaries	8,875.30	60.00	0.68%
CAC 40	7,766.21	41.96	-0.54%
DAX 40	24,084.07	76.57	-0.32%
Dow JONES (US)	44,203.61	256.04	-0.58%
FTSE 100	8,938.32	59.74	-0.66%
HKSE	24,590.12	386.80	1.60%
NASDAQ	20,784.65	144.32	0.70%
Nikkei 225	39,678.02	218.40	0.55%
NZX 50 Index	12,689.63	10.94	0.09%
S&P 500	6,269.06	0.50	0.01%
S&P/ASX 200	8,630.30	59.90	0.70%
SSE Composite Index	3,505.00	14.65	-0.42%